Download PDF
Radiopraxis 2021; 14(02): E25-E38
DOI: 10.1055/a-1394-9050
CPD-Fortbildung

Einsatz von PSMA-PET/CT beim Prostatakarzinom

Thomas Langbein
,
Matthias Eiber
› Further Information
Also available at
CPD
    Permissions and Reprints

In den letzten Jahren hat die PSMA-Liganden-PET vielversprechende Ergebnisse gezeigt und so enorm an Bedeutung bei der Versorgung von Prostatakarzinompatienten gewonnen. Dieser Beitrag soll einen Überblick zur PSMA-PET/CT in unterschiedlichen klinischen Situationen geben und auf aktuelle prospektive Studienergebnisse eingehen, welche den Stellenwert der PSMA-vermittelten Hybridbildgebung in den kommenden Jahren noch weiter steigern werden.



Publication History

Article published online:
14 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2015/2016 (12. Aufl) Berlin: Robert Koch-Institut; 2019: 98-101 DOI: 10.25646/5977
    Crossref
  • 2 Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF Leitlinienprogramm Onkologie: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0. 2018. Im Internet: (Stand: 14.09.2020). http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom
  • 3 Barnes B, Kraywinkel K, Nowossadeck E. et al. Bericht zum Krebsgeschehen in Deutschland. ; Berlin: Robert Koch-Institut; 2016. DOI: 10.17886/rkipubl-2016-014
    CrossrefGoogle Scholar
  • 4 Torre LA, Siegel RL, Ward EM. et al. Global cancer incidence and mortality rates and trends – an update. Cancer epidemiology, biomarkers & prevention. The American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 2016; 25: 16-27 DOI: 10.1158/1055-9965.Epi-15-0578.
    CrossrefPubMedGoogle Scholar
  • 5 Ferlay J, Ervik M, Lam F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2018. Im Internet: (Stand: 14.09.2020) https://gco.iarc.fr/today
  • 6 Hövels AM, Heesakkers RA, Adang EM. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-395 DOI: 10.1016/j.crad.2007.05.022.
    CrossrefPubMedGoogle Scholar
  • 7 Evangelista L, Guttilla A, Zattoni F. et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013; 63: 1040-1048 DOI: 10.1016/j.eururo.2012.09.039.
    CrossrefPubMedGoogle Scholar
  • 8 Nanni C, Zanoni L, Pultrone C. et al. 18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 2016; 43: 1601-1610 DOI: 10.1007/s00259-016-3329-1.
    CrossrefPubMedGoogle Scholar
  • 9 Silver DA, Pellicer I, Fair WR. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85
    CrossrefPubMedGoogle Scholar
  • 10 Mannweiler S, Amersdorfer P, Trajanoski S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172 DOI: 10.1007/s12253-008-9104-2.
    CrossrefPubMedGoogle Scholar
  • 11 Bostwick DG, Pacelli A, Blute M. et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-2261
    CrossrefPubMedGoogle Scholar
  • 12 Bander NH, Trabulsi EJ, Kostakoglu L. et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721 DOI: 10.1097/01.ju.0000091655.77601.0c.
    CrossrefPubMedGoogle Scholar
  • 13 Ahn T, Roberts MJ, Abduljabar A. et al. A review of prostatespecific membrane antigen (PSMA) Positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol 2019; 21: 799-807 DOI: 10.1007/s11307-018-01307-0.
    CrossrefPubMedGoogle Scholar
  • 14 Sasikumar A, Joy A, Nanabala R. et al. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 795-796 DOI: 10.1007/s00259-015-3297-x.
    CrossrefPubMedGoogle Scholar
  • 15 Shetty D, Loh H, Bui C. et al. Elevated 68Ga Prostate-Specific Membrane Antigen Activity in Metastatic Non-Small Cell Lung Cancer. Clin Nucl Med 2016; 41: 414-416 DOI: 10.1097/RLU.0000000000001139.
    CrossrefPubMedGoogle Scholar
  • 16 Kanthan GL, Coyle L, Kneebone A. et al. follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med 2016; 41: 500-501 DOI: 10.1097/RLU.0000000000001169.
    CrossrefPubMedGoogle Scholar
  • 17 Haffner MC, Kronberger IE, Ross JS. et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40: 1754-1761 DOI: 10.1016/j.humpath.2009.06.003.
    CrossrefPubMedGoogle Scholar
  • 18 Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539 DOI: 10.1002/jcb.10661.
    CrossrefPubMedGoogle Scholar
  • 19 Budäus L, Leyh-Bannurah SR, Salomon G. et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 2016; 69: 393-396 DOI: 10.1016/j.eururo.2015.06.010.
    CrossrefPubMedGoogle Scholar
  • 20 Eder M, Schafer M, Bauder-Wust U. et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem 2012; 23: 688-697 DOI: 10.1021/bc200279b.
    CrossrefPubMedGoogle Scholar
  • 21 Afshar-Oromieh A, Malcher A, Eder M. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495 DOI: 10.1007/s00259-012-2298-2.
    CrossrefPubMedGoogle Scholar
  • 22 Maurer T, Eiber M, Schwaiger M. et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13: 226-235 DOI: 10.1038/nrurol.2016.26.
    CrossrefPubMedGoogle Scholar
  • 23 Rowe SP, Gorin MA, Allaf ME. et al. PET imaging of prostatespecific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer prostatic Dis 2016; 19: 223-230 DOI: 10.1038/pcan.2016.13.
    CrossrefPubMedGoogle Scholar
  • 24 Kesch C, Kratochwil C, Mier W. et al. (68)Ga or (18)F for prostate cancer imaging?. J Nucl Med 2017; 58: 687-688 DOI: 10.2967/jnumed.117.190157.
    CrossrefPubMedGoogle Scholar
  • 25 Eiber M, Weirich G, Holzapfel K. et al. Simultaneous (68) Ga-PSMA HBED-CC PET/MRI Improves the localization of primary prostate cancer. Eur Urol 2016; 70: 829-836 DOI: 10.1016/j.eururo.2015.12.053.
    CrossrefPubMedGoogle Scholar
  • 26 Giesel FL, Sterzing F, Schlemmer HP. et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 1400-1406 DOI: 10.1007/s00259-016-3346-0.
    CrossrefPubMedGoogle Scholar
  • 27 Herlemann A, Wenter V, Kretschmer A. et al. (68)Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol 2016; 70: 553-557 DOI: 10.1016/j.eururo.2015.12.051.
    CrossrefPubMedGoogle Scholar
  • 28 Pyka T, Okamoto S, Dahlbender M. et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-2121 DOI: 10.1007/s00259-016-3435-0.
    CrossrefPubMedGoogle Scholar
  • 29 Hofman MS, Lawrentschuk N, Francis RJ. et al. Prostatespecific membrane antigen PET-CT in patients with highrisk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216 DOI: 10.1016/s0140-6736(20)30314-7.
    CrossrefPubMedGoogle Scholar
  • 30 Gorin MA, Rowe SP, Patel HD. et al. Prostate specific membrane antigen targeted (18)F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. J Urol 2018; 199: 126-132 DOI: 10.1016/j.juro.2017.07.070.
    CrossrefPubMedGoogle Scholar
  • 31 Kronke M, Wurzer A, Schwamborn K. et al. Histologicallyconfirmed diagnostic efficacy of (18)F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer. J Nucl Med 2020; 61: 710-715 DOI: 10.2967/jnumed.119.234906.
    CrossrefPubMedGoogle Scholar
  • 32 Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629 DOI: 10.1016/j.eururo.2016.08.003.
    CrossrefPubMedGoogle Scholar
  • 33 Cornford P, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630-642 DOI: 10.1016/j.eururo. 2016.08.002.
    CrossrefPubMedGoogle Scholar
  • 34 Vargas HA, Martin-Malburet AG, Takeda T. et al. Localizing sites of disease in patients with rising serum prostatespecific antigen up to 1 ng/ml following prostatectomy: How much information can conventional imaging provide?. Urol Oncol 2016; 34: e485-482.e410 DOI: 10.1016/j. urolonc.2016.05.026.
    CrossrefPubMedGoogle Scholar
  • 35 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209 DOI: 10.1007/s00259-014-2949-6.
    CrossrefPubMedGoogle Scholar
  • 36 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674 DOI: 10.2967/jnumed.115.154153.
    CrossrefPubMedGoogle Scholar
  • 37 Krause BJ, Souvatzoglou M, Tuncel M. et al. The detection rate of [11C]choline-PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18-23 DOI: 10.1007/s00259-007-0581-4.
    CrossrefPubMedGoogle Scholar
  • 38 van Leeuwen PJ, Stricker P, Hruby G. et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU international 2016; 117: 732-739 DOI: 10.1111/bju.13397.
    CrossrefPubMedGoogle Scholar
  • 39 Morigi JJ, Stricker PD, van Leeuwen PJ. et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy. J Nucl Med 2015; 56: 1185-1190 DOI: 10.2967/jnumed.115.160382.
    CrossrefPubMedGoogle Scholar
  • 40 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 2019; 5: 856-863 DOI: 10.1001/jamaoncol.2019.0096.
    CrossrefPubMedGoogle Scholar
  • 41 Calais J, Ceci F, Eiber M. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncology 2019; 20: 1286-1294 DOI: 10.1016/s1470-2045. 19: 30415-2
    CrossrefGoogle Scholar
  • 42 Giesel FL, Will L, Kesch C. et al. Biochemical recurrence of prostate cancer: initial results with [(18)F]PSMA-1007 PET/CT. J Nucl Med 2018; 59: 632-635 DOI: 10.2967/jnumed.. 117: 196329
    CrossrefGoogle Scholar
  • 43 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268 DOI: 10.1007/s00259-017-3711-7.
    CrossrefPubMedGoogle Scholar
  • 44 Fendler WP, Weber M, Iravani A. et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019; 25: 7448-7454 DOI: 10.1158/1078-0432.CCR-19-1050.
    CrossrefPubMedGoogle Scholar
  • 45 Dewes S, Schiller K, Sauter K. et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol 2016; 11: 73 DOI: 10.1186/s13014-016-0646-2.
    CrossrefPubMedGoogle Scholar
  • 46 Sterzing F, Kratochwil C, Fiedler H. et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 2016; 43: 34-41 DOI: 10.1007/s00259-015-3188-1.
    CrossrefPubMedGoogle Scholar
  • 47 von Eyben FE, Kiljunen T, Kangasmaki A. et al. Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clinl Genitourin Cancer 2016; 14: 189-197 DOI: 10.1016/j.clgc.2015.12.005.
    CrossrefPubMedGoogle Scholar
  • 48 Rauscher I, Krönke M, König M. et al. Matched-pair comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: Frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med 2020; 61: 51-57 DOI: 10.2967/jnumed.119.229187.
    CrossrefPubMedGoogle Scholar